A5082181088- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Protease and Inhibitor Mechanisms
- Viral Infectious Diseases and Gene Expression in Insects
- Bone Tissue Engineering Materials
- Monoclonal and Polyclonal Antibodies Research
- Adenosine and Purinergic Signaling
- Pluripotent Stem Cells Research
- Digital Imaging for Blood Diseases
- Protein purification and stability
- Biochemical and Structural Characterization
- Cell Adhesion Molecules Research
- Aluminum Alloys Composites Properties
- Mass Spectrometry Techniques and Applications
- Advanced Proteomics Techniques and Applications
- Burn Injury Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- CRISPR and Genetic Engineering
- COVID-19 and healthcare impacts
- Magnesium Alloys: Properties and Applications
University of Southern California
2019-2024
University of California, Los Angeles
2022-2023
Southern California University for Professional Studies
2021
Viterbo University
2021
University of California, Riverside
2016-2020
Cell Biotech (South Korea)
2020
Abstract Cancer immunotherapy with autologous chimeric antigen receptor (CAR) T cells faces challenges in manufacturing and patient selection that could be avoided by using ‘off-the-shelf’ products, such as allogeneic CAR natural killer ( Allo CAR-NKT) cells. Previously, we reported a system for differentiating human hematopoietic stem progenitor into CAR-NKT cells, but the use of three-dimensional culture xenogeneic feeders precluded its clinical application. Here describe clinically guided...
The field of T cell-based and chimeric antigen receptor (CAR)-engineered (CAR-T) antitumor immunotherapy has seen substantial developments in the past decade; however, considerable issues, such as graft-versus-host disease (GvHD) tumor-associated immunosuppression, have proven to be roadblocks widespread adoption implementation. Recent innate immune CAR therapy opened several doors for expansion this therapy, especially it relates allogeneic cell sources solid tumor infiltration. This study...
Despite the remarkable success of chimeric antigen receptor-modified T (CAR-T) cell therapy for blood malignancies, clinical efficacy this novel in solid tumor treatment is largely limited by immunosuppressive microenvironment (TME). For instance, immune checkpoints (e.g., programmed death protein 1 [PD-1]/programmed ligand [PD-L1]) TME play an important role inhibiting proliferation and functions. Transforming growth factor β (TGF)-β secreted cancer cells induces regulatory (Tregs) inhibits...
Abstract Magnesium (Mg) and its alloys have shown attractive biocompatibility mechanical strength for medical applications, but low corrosion resistance of Mg in physiological environment limits broad clinical translation. Hydroxyapatite (HA) nanoparticles (nHA) are promising coating materials decreasing degradation rates prolonging Mg-based implants while enhancing bone healing due to their osteoconductivity osteoinductivity. Conformal HA coatings with nano-to-submicron structures, namely...
New COVID-19 treatments are desperately needed as case numbers continue to rise and emergent strains threaten vaccine efficacy. Cell therapy has revolutionized cancer treatment holds much promise in combatting infectious disease, including COVID-19. Invariant natural killer T (iNKT) cells a rare subset of with potent antiviral immunoregulatory functions an excellent safety profile. Current iNKT cell strategies hindered by the extremely low presence cells, we have developed platform overcome...
Allo-HSCT is a curative therapy for hematologic malignancies owing to GvL effect mediated by alloreactive T cells; however, the same cells also mediate GvHD, severe side limiting widespread application of allo-HSCT in clinics. Invariant natural killer (iNKT) can ameliorate GvHD while preserving effect, but clinical these restricted their scarcity. Here, we report successful generation third-party HSC-engineered human iNKT (3rdHSC-iNKT) using method combining HSC gene engineering and vitro...
Abstract Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing cancer therapy due to their established safety in allogeneic contexts and inherent tumor-fighting capabilities. Nonetheless, the limited clinical success of Vδ2 cell-based treatments may be attributed donor variability, short-lived persistence, tumor immune evasion. To address these constraints, we engineer with enhanced attributes. By employing CD16 a selection biomarker, harness characterized by...
Chimeric antigen receptor (CAR) T cell therapy mediates unprecedented benefit in certain leukemias and lymphomas, but has yet to achieve similar success combating solid tumors. A substantial body of work indicates that the accumulation adenosine tumor microenvironment (TME) plays a crucial role abrogating immunotherapies. Adenosine deaminase 1 (ADA) catabolizes into inosine is indispensable for functional immune system. We have, first time, engineered CAR cells overexpress ADA. To...
Abstract The COVID-19 crisis has taken a significant toll on human life and the global economy since its start in early 2020. Healthcare professionals have been particularly vulnerable because of unprecedented shortage Facepiece Respirators (FPRs), which act as fundamental tools to protect medical staff treating coronavirus patients. In addition, many FPRs are designed be disposable single-use devices, creating an issue related generation large quantities non-biodegradable waste. this...
Playing pivotal roles in tumor growth and metastasis, matrix metalloproteinase-14 (MMP-14) is an important cancer target. Potent inhibitory Fab 3A2 with therapy-desired high selectivity has been isolated from a synthetic antibody library carrying long CDR-H3s. However, like many standard mechanism protease inhibitors, can be cleaved by concentrations of MMP-14 after extended incubation at acidic pH. Edman sequencing generated fragments indicated that cleavage occurred within its CDR-H3...
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematological malignancies but yet to achieve similar success in solid tumors due a lack persistence and function tumor microenvironment. We previously reported augmentation CAR an engineered model through secretion anti-PD-1 single-chain fragment variable region (scFv), as shown by enhanced antitumor efficacy, expansion, vitality. have since improved platform create superior cellular product-CAR cells secreting...
Abstract Matrix metalloproteinase‐12 (MMP‐12), also known as macrophage elastase, is a potent inflammatory mediator and therefore an important pharmacological target. Clinical trial failures of broad‐spectrum compound MMP inhibitors suggested that specificity the key for successful therapy. To provide required selectivity, monoclonal antibody (mAb)‐based are on rise. However, poor production active recombinant human MMP‐12 catalytic domain (cdMMP‐12) presented technical hurdle its inhibitory...
Abstract Chimeric antigen receptors (CARs) are synthetic biomolecules comprised of an extracellular recognition domain and intracellular signaling domains. When expressed in immune cells, CARs direct their host cells to kill diseased expressing the recognized by CAR. Although pathways downstream CAR activation control cytotoxic function CAR-expressing phospho-proteomic studies have been limited. Most approaches used antibodies or soluble ligands, rather than cell-displayed antigens, activate...
Intraperitoneal (i.p.) experimental models in mice can recapitulate the process of i.p. dissemination abdominal cancers and may help uncover critical information about future successful clinical treatments. cellular composition is studied preclinical addressing a wide spectrum other pathophysiological states such as liver cirrhosis, infectious disease, autoimmunity, aging. The peritoneal cavity multifaceted microenvironment that contains various immune cell populations, including T, B, NK,...
<h3>Background</h3> Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematological malignancies but yet to achieve similar success in solid tumors due a lack persistence and function tumor microenvironment. We previously reported augmentation CAR an engineered model through secretion anti-PD-1 scFv, as shown by enhanced antitumor efficacy, expansion, vitality.<sup>1</sup> have since matured platform create superior cellular product – cells secreting...
Regula on and remodeling of intermediate metabolite membrane lipid during NaCl-